Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387516756> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4387516756 abstract "Abstract Background The Surgery in Early Metastatic Seminoma (SEMS) trial examined retroperitoneal lymph node dissection (RPLND) as first-line treatment for patients with isolated 1-3cm retroperitoneal lymphadenopathy. To date, the standard of care for these patients has been either chemotherapy or radiotherapy (XRT). Herein, we evaluated the relative cost-effectiveness of these management strategies. Methods A microsimulation model assessed the cost-effectiveness of RPLND, chemotherapy, and XRT for stage IIA seminoma. Sensitivity analyses were performed to evaluate model robustness. RPLND recurrence probabilities were obtained from the SEMS trial. All other probability and utility values were obtained from published literature. Primary outcomes included costs from a commercial insurer’s perspective, effectiveness (quality adjusted life years, QALYs), and incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $100,000/QALY. Results At a lifetime horizon, the mean costs per patient for RPLND, XRT, and chemotherapy were $58,469, $98,783, and $104,096 and the mean QALYs were 40.61, 40.70, and 39.15, respectively. RPLND was found to be the most cost-effective approach due to high costs and accrued disutility of chronic toxicities associated with both XRT (ICER: $433,845/QALY) and chemotherapy (dominated). On one-way sensitivity analyses, RPLND was no longer cost-effective if the probabilities of infertility and cardiovascular toxicity after XRT were less than 13% and 16%, respectively, or if the 2-year probability of progression after RPLND was over 26%. Conclusions RPLND was the most cost-effective treatment approach for stage IIA seminoma. These findings support clinical guideline consideration of including RPLND as a treatment option for well selected patients with stage IIA seminoma." @default.
- W4387516756 created "2023-10-12" @default.
- W4387516756 creator A5005864006 @default.
- W4387516756 creator A5006063761 @default.
- W4387516756 creator A5047940829 @default.
- W4387516756 creator A5054059203 @default.
- W4387516756 creator A5062824073 @default.
- W4387516756 creator A5063867635 @default.
- W4387516756 creator A5073960684 @default.
- W4387516756 creator A5077644150 @default.
- W4387516756 creator A5078054821 @default.
- W4387516756 creator A5082402405 @default.
- W4387516756 creator A5088860939 @default.
- W4387516756 date "2023-10-11" @default.
- W4387516756 modified "2023-10-13" @default.
- W4387516756 title "Comparative Cost-effectiveness of Contemporary Treatment Strategies for Stage IIA Seminoma" @default.
- W4387516756 doi "https://doi.org/10.1093/jnci/djad211" @default.
- W4387516756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37819776" @default.
- W4387516756 hasPublicationYear "2023" @default.
- W4387516756 type Work @default.
- W4387516756 citedByCount "0" @default.
- W4387516756 crossrefType "journal-article" @default.
- W4387516756 hasAuthorship W4387516756A5005864006 @default.
- W4387516756 hasAuthorship W4387516756A5006063761 @default.
- W4387516756 hasAuthorship W4387516756A5047940829 @default.
- W4387516756 hasAuthorship W4387516756A5054059203 @default.
- W4387516756 hasAuthorship W4387516756A5062824073 @default.
- W4387516756 hasAuthorship W4387516756A5063867635 @default.
- W4387516756 hasAuthorship W4387516756A5073960684 @default.
- W4387516756 hasAuthorship W4387516756A5077644150 @default.
- W4387516756 hasAuthorship W4387516756A5078054821 @default.
- W4387516756 hasAuthorship W4387516756A5082402405 @default.
- W4387516756 hasAuthorship W4387516756A5088860939 @default.
- W4387516756 hasConcept C112930515 @default.
- W4387516756 hasConcept C141071460 @default.
- W4387516756 hasConcept C143998085 @default.
- W4387516756 hasConcept C146357865 @default.
- W4387516756 hasConcept C151730666 @default.
- W4387516756 hasConcept C2776212926 @default.
- W4387516756 hasConcept C2776694085 @default.
- W4387516756 hasConcept C2778074268 @default.
- W4387516756 hasConcept C2779511695 @default.
- W4387516756 hasConcept C3019080777 @default.
- W4387516756 hasConcept C509974204 @default.
- W4387516756 hasConcept C64332521 @default.
- W4387516756 hasConcept C71924100 @default.
- W4387516756 hasConcept C86803240 @default.
- W4387516756 hasConceptScore W4387516756C112930515 @default.
- W4387516756 hasConceptScore W4387516756C141071460 @default.
- W4387516756 hasConceptScore W4387516756C143998085 @default.
- W4387516756 hasConceptScore W4387516756C146357865 @default.
- W4387516756 hasConceptScore W4387516756C151730666 @default.
- W4387516756 hasConceptScore W4387516756C2776212926 @default.
- W4387516756 hasConceptScore W4387516756C2776694085 @default.
- W4387516756 hasConceptScore W4387516756C2778074268 @default.
- W4387516756 hasConceptScore W4387516756C2779511695 @default.
- W4387516756 hasConceptScore W4387516756C3019080777 @default.
- W4387516756 hasConceptScore W4387516756C509974204 @default.
- W4387516756 hasConceptScore W4387516756C64332521 @default.
- W4387516756 hasConceptScore W4387516756C71924100 @default.
- W4387516756 hasConceptScore W4387516756C86803240 @default.
- W4387516756 hasLocation W43875167561 @default.
- W4387516756 hasLocation W43875167562 @default.
- W4387516756 hasOpenAccess W4387516756 @default.
- W4387516756 hasPrimaryLocation W43875167561 @default.
- W4387516756 hasRelatedWork W1973602149 @default.
- W4387516756 hasRelatedWork W2157291614 @default.
- W4387516756 hasRelatedWork W2248719375 @default.
- W4387516756 hasRelatedWork W2591172339 @default.
- W4387516756 hasRelatedWork W2940674388 @default.
- W4387516756 hasRelatedWork W29561876 @default.
- W4387516756 hasRelatedWork W2989426612 @default.
- W4387516756 hasRelatedWork W4210490832 @default.
- W4387516756 hasRelatedWork W4224443899 @default.
- W4387516756 hasRelatedWork W4239990177 @default.
- W4387516756 isParatext "false" @default.
- W4387516756 isRetracted "false" @default.
- W4387516756 workType "article" @default.